NASDAQ:INMB
Inmune Bio, Inc.
Inmune Bio, Inc.'s revenue grew 257.1% in fiscal 2025 to $50,000 while operating margin rose to −94766.0%. Free cash flow was −$23.6M, −47248.0% of revenue, and the diluted share count rose 24.1%.Summary generated from Inmune Bio, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$50,000
Revenue growth+257.1%
Revenue, 5-yr CAGR+35.4%
Gross marginn/a
Operating margin−94766.0%
Net margin−91866.0%
ROICn/a
Return on equity−165.2%
Debt / equityn/a
Free cash flow−$23.6M
FCF margin−47248.0%
Share count change+24.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −29 | −26 | −30 | −43 | −47 |
| Net income | −30 | −27 | −30 | −42 | −46 |
| Free cash flow | n/a | n/a | n/a | n/a | −24 |
Recent filings
- 4Insider transaction report
Sep 23, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KDirector or officer change
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KOther events
Jul 31, 2026 - 8-KEntry into a material agreement
Jul 1, 2026 - 8-KOther events
Jun 23, 2026 - 8-KDirector or officer change
Jun 17, 2026